Skip to main content
Erschienen in:

06.11.2020 | original article

Effect of intravitreal anti-vascular endothelial growth factor administration on the vitreomacular interface and retinal morphology in eyes with neovascular age-related macular degeneration

verfasst von: Clara Wernigg, MD, Christopher Schütze, MD, PhD, Prof. Pia-Veronika Vécsei-Marlovits, MD, MBA, Birgit Weingessel, MD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Summary

Background

To assess the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) administration on the vitreomacular interface and retinal morphology in eyes with neovascular age-related macular degeneration (AMD) and to identify morphological markers potentially influencing disease prognosis.

Material and methods

A total of 43 patients (51 eyes) with treatment-naïve neovascular AMD subsequently treated with bevacizumab 1.25 mg (in 0.05 ml of solution) were monitored until month 12 of follow-up. Following a loading dose of three monthly intravitreal anti-VEGF injections, patients were treated as-needed (pro re nata [PRN]). Functional and morphological changes were assessed using spectral domain optical coherence tomography (SD-OCT).

Results

All study eyes showed evidence of an increase in the frequency of geographic atrophy (GA) occurrence during follow-up compared to baseline (n = 23 [45%] at month 12 compared to n = 5 [9.8%] at baseline [p > 0.05]). There was a trend towards more frequent GA in eyes diagnosed with posterior vitreomacular adhesion (PVA) at baseline that developed posterior vitreous detachment (PVD) during follow-up compared to eyes not developing PVD (35% vs. 44% GA, p 0.56).

Conclusions

Alterations of the vitreomacular interface and retinal morphology in patients with neovascular AMD treated with bevacizumab may have a significant effect on prognosis with respect to GA development. Eyes with vitreomacular adhesion at baseline developing GA during follow-up might require more intensive anti-VEGF therapy with a decreased ability to extend treatment intervals. Findings are comparable to eyes treated with other anti-VEGF agents administered for the management of neovascular AMD.
Literatur
1.
Zurück zum Zitat Arai M, Yamamoto S, Mitamura Y, Sato E, Sugawara T, Mizunoya S. Efficacy of vitrectomy and internal limiting membrane removal for macular edema associated with branch retinal vein occlusion. Ophthalmologica. 2009;223(3):172–6.CrossRef Arai M, Yamamoto S, Mitamura Y, Sato E, Sugawara T, Mizunoya S. Efficacy of vitrectomy and internal limiting membrane removal for macular edema associated with branch retinal vein occlusion. Ophthalmologica. 2009;223(3):172–6.CrossRef
2.
Zurück zum Zitat Foos RY, Wheeler NC. Vitreoretinal juncture. Synchysis senilis and posterior vitreous detachment. Ophthalmology. 1982;89(12):1502–12.CrossRef Foos RY, Wheeler NC. Vitreoretinal juncture. Synchysis senilis and posterior vitreous detachment. Ophthalmology. 1982;89(12):1502–12.CrossRef
3.
Zurück zum Zitat Gallemore RP, Jumper JM, McCuen BW 2nd, Jaffe GJ, Postel EA, Toth CA. Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina. 2000;20(2):115–20.CrossRef Gallemore RP, Jumper JM, McCuen BW 2nd, Jaffe GJ, Postel EA, Toth CA. Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina. 2000;20(2):115–20.CrossRef
4.
Zurück zum Zitat Gawecki M, Doroszkiewicz M, Rydzewski J. Age related macular degeneration and presence of posterior vitreous detachment. Klin Oczna. 2010;112(7–9):210–2.PubMed Gawecki M, Doroszkiewicz M, Rydzewski J. Age related macular degeneration and presence of posterior vitreous detachment. Klin Oczna. 2010;112(7–9):210–2.PubMed
5.
Zurück zum Zitat Diabetic Retinopathy Clinical Research Network, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087–1093.e3.CrossRef Diabetic Retinopathy Clinical Research Network, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087–1093.e3.CrossRef
6.
Zurück zum Zitat Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144(5):741–6.CrossRef Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144(5):741–6.CrossRef
7.
Zurück zum Zitat Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand. 1999;77(2):170–5.CrossRef Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand. 1999;77(2):170–5.CrossRef
8.
Zurück zum Zitat Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146(2):218–27.CrossRef Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146(2):218–27.CrossRef
9.
Zurück zum Zitat Ondeş F, Yilmaz G, Acar MA, Unlü N, Kocaoğlan H, Arsan AK. Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol. 2000;44(1):91–3.CrossRef Ondeş F, Yilmaz G, Acar MA, Unlü N, Kocaoğlan H, Arsan AK. Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol. 2000;44(1):91–3.CrossRef
10.
Zurück zum Zitat Gao M, Liu L, Liang X, Yu Y, Liu X, Liu W. Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration. Medicine. 2017;96(50):e9345.CrossRef Gao M, Liu L, Liang X, Yu Y, Liu X, Liu W. Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration. Medicine. 2017;96(50):e9345.CrossRef
12.
Zurück zum Zitat Dolz-Marco R, Balaratnasingam C, Gattoussi S, Ahn S, Yannuzzi LA, Freund KB. Long-term choroidal thickness changes in eyes with drusenoid pigment epithelium detachment. Am J Ophthalmol. 2018;191:23–33.CrossRef Dolz-Marco R, Balaratnasingam C, Gattoussi S, Ahn S, Yannuzzi LA, Freund KB. Long-term choroidal thickness changes in eyes with drusenoid pigment epithelium detachment. Am J Ophthalmol. 2018;191:23–33.CrossRef
14.
Zurück zum Zitat CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.CrossRef CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.CrossRef
15.
Zurück zum Zitat IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.CrossRef IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.CrossRef
16.
Zurück zum Zitat Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96(2):120–33.CrossRef Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96(2):120–33.CrossRef
17.
Zurück zum Zitat Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809–16.CrossRef Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809–16.CrossRef
Metadaten
Titel
Effect of intravitreal anti-vascular endothelial growth factor administration on the vitreomacular interface and retinal morphology in eyes with neovascular age-related macular degeneration
verfasst von
Clara Wernigg, MD
Christopher Schütze, MD, PhD
Prof. Pia-Veronika Vécsei-Marlovits, MD, MBA
Birgit Weingessel, MD
Publikationsdatum
06.11.2020
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 2/2021
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-020-00471-5

Weitere Artikel der Ausgabe 2/2021

Spektrum der Augenheilkunde 2/2021 Zur Ausgabe